NCT05889052View on ClinicalTrials.gov

Perennial Malaria Chemoprevention (PMC) in Cameroon

Active, not recruitingOBSERVATIONAL
Enrollment

2,080

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
AnemiaMalaria
Interventions
DRUG

Sulfadoxine pyrimethamine

Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)

Trial Locations (1)

Unknown

Multiple, Soa and Mbankomo

All Listed Sponsors
collaborator

Fobang Institutes Centre for Health Implementation and Translational Research

UNKNOWN

lead

London School of Hygiene and Tropical Medicine

OTHER